Europe Insomnia Market Summary
The Europe EMEA Insomnia market is poised for substantial growth, projected to reach 2.09 USD Billion by 2035 from a base of 0.5 USD Billion in 2024.
Key Market Trends & Highlights
EMEA Insomnia Key Trends and Highlights
- The Europe EMEA Insomnia market is valued at 0.5 USD Billion in 2024 and is expected to grow to 2.09 USD Billion by 2035.
- The market is anticipated to experience a compound annual growth rate (CAGR) of 13.91% from 2025 to 2035.
- Increasing awareness of sleep disorders is likely to drive market expansion, contributing to the overall growth.
- Growing adoption of innovative sleep solutions due to rising health consciousness is a major market driver.
Market Size & Forecast
2024 Market Size | 0.5 (USD Billion) |
2035 Market Size | 2.09 (USD Billion) |
CAGR (2025-2035) | 13.91% |
Major Players
Pfizer Inc. (U.K), Sanofi (France), GlaxoSmithKline Plc. (UK), Astellas (UK), Biocodex S A (France), Neurim (Switzerland), Flynn Pharma (UK), CAD Middle East Pharmaceutical Industries LLC (Saudi Arabia), Tabuk Pharmaceutical (Jordan)